Insider Cluster (2 insiders) ·Filed May 15, 2026

PTCT

PTC THERAPEUTICS, INC.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago
Insider cluster: 2 insiders, $115K total
Actionable Insight • Neutral

The insider sales are too small to warrant concern. The strong Q1 earnings and raised guidance dominate the narrative. Monitor for any larger insider sales in the coming weeks, but this cluster alone does not signal a change in outlook.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
PTCT ▲ +3.55% at T+60d
NEUTRAL call ✓ call won +3.55% · α vs SPY -1.30% · entry $70.15 → $72.64
Entry anchored
May 15, 2026
via day open
T+1d
+0.23%
call +0.23% · α +0.88%
$70.31
settled 5mo ago
T+5d
-3.56%
call -3.56% · α -5.18%
$67.65
settled 4mo ago
T+20d
+4.45%
call +4.45% · α +2.87%
$73.27
settled 4mo ago
T+60d
+3.55%
call +3.55% · α -1.30%
$72.64
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Two PTCT insiders, including CEO Matthew Klein, sold a combined ~$115K in open-market sales within a week of the company's strong Q1 2026 earnings report. The sales are trivial relative to the $6.0B market cap (~0.002%) and are likely routine portfolio diversification following a 47% YoY product revenue surge and raised guidance. The cluster is not informative of bearish sentiment.

Key Financial Metrics

Direction
selling
Total Value
$115.0K
Insiders
2

Key Facts

  • CEO Matthew Klein sold 679 shares at $73.06 for ~$50K on 2026-05-14.
  • EVP & CLO Mark Elliott Boulding sold 840 shares at $78.23 for ~$66K on 2026-05-08.
  • Total open-market sales: ~$115K, representing ~0.002% of PTCT's $6.0B market cap.
  • CEO also received a non-cash grant of 12,500 shares on 2026-05-13.
  • Q1 2026 total revenue was $273M, up 44% YoY; product revenue rose 47% YoY to $226M.
  • Full-year product revenue guidance raised to $750-$850M.
  • Net loss was $2.8M in Q1 2026 vs. net income of $866.6M in Q1 2025 (prior year included a large one-time gain).

Financial Impact

Insider sales of ~$115K are immaterial relative to $6.0B market cap.

Risk Factors

  • Translarna revenue declined 32% YoY ($59M vs. $86M) due to generic competition.
  • Emflaza revenue declined 55% YoY ($21.5M vs. $47.8M) due to generic erosion.
  • Net loss of $2.8M vs. prior-year net income of $866.6M (though prior year included a large one-time gain).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (22 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PTCT-1778880045161
15 reports for PTCT
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+60▲ +19.01%Apr 28, 2026
Filters
Rows
Reports for PTCT — sortable, filterable
TypeNow
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$69.82 $65.26▼ −6.53%▼ −6.00%$63.46 (−9.11%)
Jul 16, 2026
11w ago
Press Release
BEARISH ★ 7/10
$78.52 $71.97▲ +8.34%▲ +11.96%$63.46 (+19.18%)
Jul 16, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$78.52 $71.97▼ −8.34%▼ −11.96%$63.46 (−19.18%)
Jul 13, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$81.33 $74.63▼ −8.24%▼ −11.42%$63.46 (−21.97%)
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$88.57 $69.21▼ −21.86%▼ −25.13%$63.46 (−28.35%)
Jun 26, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$81.57 $76.82▼ −5.82%▼ −5.54%$63.46 (−22.20%)
Jun 16, 2026
15w ago
8-K
NEUTRAL ★ 5/10
$73.27 $78.06▲ +6.54%▲ +6.34%$63.46 (−13.39%)
Jun 9, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$73.35 $89.55▲ +22.09%▲ +18.46%$63.46 (−13.48%)
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.02 $78.98▲ +11.21%▲ +10.47%$63.46 (−10.64%)
May 15, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$70.15 $73.27▲ +4.45%▲ +2.87%$63.46 (−9.54%)
Showing 10 of 15

US Market Status

Market Closed — Opens Mon (65h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 15, 2026